Effect of human rotavirus vaccine on severe diarrhea in African infants.

BACKGROUND Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. METHODS We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine in preventing severe rotavirus gastroenteritis. Healthy infants were randomly assigned in a 1:1:1 ratio to receive two doses of vaccine (in addition to one dose of placebo) or three doses of vaccine - the pooled vaccine group - or three doses of placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life were assessed through active follow-up surveillance and were graded with the use of the Vesikari scale. RESULTS A total of 4939 infants were enrolled and randomly assigned to one of the three groups; 1647 infants received two doses of the vaccine, 1651 infants received three doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of the infants in the placebo group and in 1.9% of those in the pooled vaccine group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the number of episodes of severe rotavirus gastroenteritis that were prevented was greater in Malawi than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause severe gastroenteritis was 30.2%. At least one serious adverse event was reported in 9.7% of the infants in the pooled vaccine group and in 11.5% of the infants in the placebo group. CONCLUSIONS Human rotavirus vaccine significantly reduced the incidence of severe rotavirus gastroenteritis among African infants during the first year of life. (ClinicalTrials.gov number, NCT00241644.).

[1]  M. Molyneux,et al.  Epidemiology of rotavirus infection in children in Blantyre, Malawi, 1997-2007. , 2010, The Journal of infectious diseases.

[2]  C. Sanderson,et al.  Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data , 2009, The Lancet.

[3]  R. Ward,et al.  Live Attenuated Human Rotavirus Vaccine, RIX4414, Provides Clinical Protection in Infants Against Rotavirus Strains With and Without Shared G and P Genotypes: Integrated Analysis of Randomized Controlled Trials , 2009, The Pediatric infectious disease journal.

[4]  D. Sack,et al.  Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age. , 2009, Vaccine.

[5]  J. Dewar,et al.  The detection and molecular characterization of human G12 genotypes in South Africa , 2009, Journal of medical virology.

[6]  B. Ngwira,et al.  Serotype G12 Rotaviruses, Lilongwe, Malawi , 2009, Emerging infectious diseases.

[7]  D. M. Rivera-Medina,et al.  Oral Human Rotavirus Vaccine RIX4414(Rotarix™) Co-administered with Routine EPI Vaccinations Including Oral Polio Vaccine(OPV) Is Highly Efficacious in Latin-America , 2008 .

[8]  D. Anh,et al.  Immunogenicity, Reactogenicity and Safety of the Oral Live Attenuated Human Rotavirus Vaccine RIX4414(Rotarix™) Oral Suspension (Liquid Formulation) in Vietnamese Infants , 2008 .

[9]  T. Vesikari,et al.  Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study , 2007, The Lancet.

[10]  C. Oliveira,et al.  Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. , 2007, Jornal de pediatria.

[11]  M. O’Ryan Rotarix™ (RIX4414): an oral human rotavirus vaccine , 2007, Expert review of vaccines.

[12]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[13]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[14]  R. Glass,et al.  Rotavirus vaccines: targeting the developing world. , 2005, The Journal of infectious diseases.

[15]  Roger I Glass,et al.  Serotype diversity and reassortment between human and animal rotavirus strains: implications for rotavirus vaccine programs. , 2005, The Journal of infectious diseases.

[16]  A. Steele,et al.  Rotavirus strains circulating in Africa during 1996-1999: emergence of G9 strains and P[6] strains. , 2003, Vaccine.

[17]  J. Alexander,et al.  Anticipating rotavirus vaccines: epidemiology and surveillance of rotavirus in South Africa. , 2003, Vaccine.

[18]  B. Schwartz,et al.  Intussusception among infants given an oral rotavirus vaccine. , 2001, The New England journal of medicine.

[19]  X. Pang,et al.  Rotaviruses detected by reverse transcription polymerase chain reaction in acute gastroenteritis during a trial of rhesus-human reassortant rotavirus tetravalent vaccine: implications for vaccine efficacy analysis. , 1999, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[20]  R. Glass,et al.  Rotavirus infection in infants as protection against subsequent infections. , 1996, The New England journal of medicine.

[21]  Suharyono,et al.  Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children , 1992, The Lancet.

[22]  S. Hoffman,et al.  Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine , 1991, The Lancet.

[23]  K. Chopra,et al.  Antibody response of infants in tropics to five doses of oral polio vaccine. , 1989, Journal of tropical pediatrics.

[24]  J. Alexander,et al.  Rotavirus-associated gastroenteritis in black infants in South Africa , 1986, Journal of clinical microbiology.

[25]  S. P. Deolalkar Recommendations and Conclusions , 2015 .

[26]  Releve Epidemiologique Hebdomadaire Global networks for surveillance of rotavirus gastroenteritis, 2001-200. , 2008, Releve epidemiologique hebdomadaire.

[27]  Meeting of the immunization Strategic Advisory Group of Experts, November 2006--conclusions and recommendations. , 2007, Releve epidemiologique hebdomadaire.

[28]  Y. Hoshino,et al.  Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine , 2005, Reviews in medical virology.

[29]  M. Georges-Courbot,et al.  Evaluation of the efficacy of a low-passage bovine rotavirus (strain WC3) vaccine in children in Central Africa. , 1991, Research in virology.

[30]  T. Vesikari,et al.  Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. , 1990, Scandinavian journal of infectious diseases.

[31]  D. Bernstein,et al.  Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. , 1989, The Journal of infectious diseases.